Society for Neuroscience 2019 Archives

Robust chemically induced animal model of Gaucher disease for preclinical study

by admin | Jun 2, 2019

S. RAMBOZ, A. PENNINGTON, K. COX, M. HALL, W. ARIAS, K. KAYSER, J. GUTERL, M. BANSAL, D. HAVAS, K. CIRILLO Parkinson’s disease (PD) and synucleinophathies are neurodegenerative disorders defined by α-synuclein (α-syn) accumulation. Mutations in the α-syn gene have...

Behavioral assessment of the 61SNCA mouse model of Parkinson’s disease employing the NeuroCube® system of movement analysis

by admin | Jun 2, 2019

W. J. XU, A. EDWARDS, K. COX, K. CIRILLO, J. A. AVILA, S. RAMBOZ Parkinson’s disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuronal loss in the substantia nigra with accumulation of α synuclein containing Lewy bodies. A number of rodent...

Characterization of Htt-Q130-LEH, a novel heterozygous knock-in rat model of Huntington’s disease

by admin | Jun 2, 2019

T. HEIKKINEN, T. BRAGGE, S. KOPONEN, T. PARKKARI, G. TOMBAUGH, S. GELMAN, S. ZHONG, L. DEVI, A. GHAVAMI, K. CIRILLO, A. BARRE, F. GACKIERE, D. GUIMOND, S. ZAPETTINI, B. SAVA, P. CHAUSSON, E. STEIDL, B. BUISSON, K. KUHLBRODT, A. KAKOULIDOU, S. JOBUSCH, K. TILLACK, A....

Rare functional angiotensin I converting enzyme genetic variants increase the risk of Alzheimer’s disease

by admin | Jun 2, 2019

L. K. CUDDY, D. PROKOPENKO, R. BRIMBERRY, E. CUNNINGHAM, P. SONG, D. PROCISSI, T. HANANIA, S. C. LEISER, R. E. TANZI, R. J. VASSAR The angiotensin I converting enzyme (ACE1) gene (ACE) has been recently established as a genome-wide significant Alzheimer’s disease (AD)...

SEP-363856, a novel psychotropic agent with a unique, non-D2 mechanism of action

by admin | Jun 2, 2019

N. DEDIC1, P. G. JONES1, S. C. HOPKINS1, R. LEW1, T. HANANIA2, U. C. CAMPBELL1, K. S. KOBLAN1 1Sunovion Pharmaceuticals Inc., Marlborough, MA; 2Psychogenics Inc., Paramus, NJ. For the past 50 years, the clinical efficacy of antipsychotic medications has relied on...

Robust chemically induced animal model of Gaucher disease for preclinical study

Behavioral assessment of the 61SNCA mouse model of Parkinson’s disease employing the NeuroCube® system of movement analysis

Characterization of Htt-Q130-LEH, a novel heterozygous knock-in rat model of Huntington’s disease

Rare functional angiotensin I converting enzyme genetic variants increase the risk of Alzheimer’s disease

SEP-363856, a novel psychotropic agent with a unique, non-D2 mechanism of action

Recent Comments

CONTACT

Email: info@psychogenics.com

Phone: (914) 406-8019